The stock of Calithera Biosciences Inc (NASDAQ:CALA) is a huge mover today! The stock increased 11.76% or $0.3 on October 28, hitting $2.85. About 227,521 shares traded hands. Calithera Biosciences Inc (NASDAQ:CALA) has declined 50.77% since March 28, 2016 and is downtrending. It has underperformed by 55.48% the S&P500.
The move comes after 8 months positive chart setup for the $61.58M company. It was reported on Oct, 28 by Barchart.com. We have $7.58 PT which if reached, will make NASDAQ:CALA worth $102.22 million more.
Analysts await Calithera Biosciences Inc (NASDAQ:CALA) to report earnings on November, 14. They expect $-0.47 earnings per share, up 4.08% or $0.02 from last year’s $-0.49 per share. After $-0.55 actual earnings per share reported by Calithera Biosciences Inc for the previous quarter, Wall Street now forecasts -14.55% EPS growth.
Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage
Out of 3 analysts covering Calithera Biosciences (NASDAQ:CALA), 2 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 67% are positive. Calithera Biosciences has been the topic of 4 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The stock of Calithera Biosciences Inc (NASDAQ:CALA) earned “Sell” rating by Citigroup on Tuesday, October 25. On Friday, July 24 the stock rating was initiated by Citigroup with “Buy”.
According to Zacks Investment Research, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 0.47 in Q2 2016. Its down 0.57, from 1.04 in 2016Q1. The ratio dropped, as 16 funds sold all Calithera Biosciences Inc shares owned while 18 reduced positions. 9 funds bought stakes while 7 increased positions. They now own 7.04 million shares or 18.29% less from 8.61 million shares in 2016Q1.
Morgan Stanley accumulated 5,621 shares or 0% of the stock. Gsa Prtnrs Llp, a United Kingdom-based fund reported 43,800 shares. California Employees Retirement holds 14,100 shares or 0% of its portfolio. Alpine Prtn Vi Ltd Llc last reported 0.03% of its portfolio in the stock. Moreover, Amici Capital Lc has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 6,360 shares. Moreover, Pnc Fincl Svcs Grp has 0% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 5 shares. Bvf Il accumulated 0.1% or 121,400 shares. Credit Suisse Ag accumulated 0% or 53,183 shares. Wells Fargo Mn reported 53,405 shares or 0% of all its holdings. The New Jersey-based Jacobs Levy Equity Management Inc has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Tower Rech Cap (Trc) accumulated 0% or 1,009 shares. Millennium Management Limited Liability Com last reported 0% of its portfolio in the stock. Blackrock Advsr Limited Liability Corporation last reported 2,540 shares in the company. Blackrock Institutional Tru Company Na reported 230,825 shares or 0% of all its holdings. Susquehanna Group Llp reported 27,090 shares or 0% of all its holdings.
More news for Calithera Biosciences Inc (NASDAQ:CALA) were recently published by: Quotes.Wsj.com, which released: “News Calithera Biosciences Inc.CALA” on February 17, 2011. Prnewswire.com‘s article titled: “ProTrials Research, Inc. Selected by Calithera Biosciences, Inc. for Early …” and published on July 25, 2016 is yet another important article.
CALA Company Profile
Calithera Biosciences, Inc., incorporated on March 9, 2010, is a clinical-stage pharmaceutical company. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. The Firm is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company’s lead product candidate, CB-839, is a critical enzyme in tumor cells. The Company’s other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. The Company’s lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.